LUMO Lumos Pharma Inc

Price (delayed)

$1.65

Market cap

$13.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.59

Enterprise value

-$9.27M

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management ...

Highlights
LUMO's quick ratio has dropped by 54% year-on-year but it is up by 2.5% since the previous quarter
The debt has grown by 23% year-on-year but it has declined by 11% since the previous quarter
The equity has plunged by 67% YoY and by 36% from the previous quarter
The revenue has contracted by 27% YoY and by 26% from the previous quarter

Key stats

What are the main financial stats of LUMO
Market
Shares outstanding
8.12M
Market cap
$13.39M
Enterprise value
-$9.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
8.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.08
Earnings
Revenue
$1.53M
EBIT
-$37.16M
EBITDA
-$37.12M
Free cash flow
-$34.79M
Per share
EPS
-$4.59
Free cash flow per share
-$4.29
Book value per share
$2.15
Revenue per share
$0.19
TBVPS
$3.46
Balance sheet
Total assets
$28.08M
Total liabilities
$10.64M
Debt
$518,000
Equity
$17.44M
Working capital
$23.13M
Liquidity
Debt to equity
0.03
Current ratio
6.24
Quick ratio
5.29
Net debt/EBITDA
0.61
Margins
EBITDA margin
-2,434.2%
Gross margin
100%
Net margin
-2,434.7%
Operating margin
-2,586.3%
Efficiency
Return on assets
-85.9%
Return on equity
-119.9%
Return on invested capital
-791.6%
Return on capital employed
-157%
Return on sales
-2,436.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LUMO stock price

How has the Lumos Pharma stock price performed over time
Intraday
-6.78%
1 week
-25.34%
1 month
-34.26%
1 year
-51.47%
YTD
-48.11%
QTD
-28.88%

Financial performance

How have Lumos Pharma's revenue and profit performed over time
Revenue
$1.53M
Gross profit
$1.53M
Operating income
-$39.44M
Net income
-$37.13M
Gross margin
100%
Net margin
-2,434.7%
LUMO's operating margin has shrunk by 68% YoY and by 45% QoQ
The net margin has dropped by 67% year-on-year and by 47% since the previous quarter
The revenue has contracted by 27% YoY and by 26% from the previous quarter
LUMO's gross profit is down by 27% YoY and by 26% from the previous quarter

Growth

What is Lumos Pharma's growth rate over time

Valuation

What is Lumos Pharma stock price valuation
P/E
N/A
P/B
0.77
P/S
8.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.08
LUMO's EPS is down by 25% year-on-year and by 10% since the previous quarter
The equity has plunged by 67% YoY and by 36% from the previous quarter
The P/B is 14% less than the 5-year quarterly average of 0.9 and 14% less than the last 4 quarters average of 0.9
The P/S is 98% lower than the 5-year quarterly average of 529.1 and 36% lower than the last 4 quarters average of 13.7
The revenue has contracted by 27% YoY and by 26% from the previous quarter

Efficiency

How efficient is Lumos Pharma business performance
LUMO's ROE has shrunk by 148% YoY and by 40% QoQ
LUMO's ROA has dropped by 111% year-on-year and by 32% since the previous quarter
LUMO's ROIC has shrunk by 91% QoQ and by 73% YoY
LUMO's return on sales has dropped by 67% year-on-year and by 47% since the previous quarter

Dividends

What is LUMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUMO.

Financial health

How did Lumos Pharma financials performed over time
The company's total assets is 164% higher than its total liabilities
The company's total assets has shrunk by 56% YoY and by 31% QoQ
LUMO's quick ratio has dropped by 54% year-on-year but it is up by 2.5% since the previous quarter
The debt is 97% smaller than the equity
Lumos Pharma's debt to equity has soared by 200% YoY and by 50% from the previous quarter
The equity has plunged by 67% YoY and by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.